Company intelligence / Profile preview
Saisei Pharma
- Ownership
- Private
- Development stage
- Other
Overview
Saisei Pharma has developed patented generations of GcMAF-based products, including injectable and oral forms, with a focus on immune modulation for cancer, infectious diseases, autism, and other chronic conditions. Clinical trials have been conducted for oral MAF in COVID‑19 patients; however, most offerings are classified as food supplements rather than approved pharmaceuticals. The company emphasizes safety and individualized integrative medicine approaches.
- Therapeutic areas
- NeurologyPsychiatryInfectious DiseasesOncologyImmunology
- Modalities
- Protein (GcMAF, MAF series)Food supplement therapyDevice (ultrasonic sensitizers, electric field therapy such as TTF and ECCT)Gene therapy (liposomal gene therapy)
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Saisei Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Saisei Pharma.